Is levodopa toxic to human substantia nigra?

Movement Disorders

Volumn 12, Issue 5, 1997, Pages 634-638

  Rajput, A H ^a   Fenton, M E ^a   Birdi, S ^a   Macaulay, R ^a  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

Levodopa; Parkinson's disease; Substantia nigra

Indexed keywords

LEVODOPA;

ADULT; ARTICLE; AUTOPSY; CLINICAL ARTICLE; CLINICAL FEATURE; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG TOXICITY; DYSTONIA; ESSENTIAL TREMOR; FEMALE; HUMAN; MALE; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRESCHOOL CHILD; PRIORITY JOURNAL; SUBSTANTIA NIGRA; TISSUE CULTURE;

ADULT; AGED; AGED, 80 AND OVER; CHILD; DYSTONIA; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; SUBSTANTIA NIGRA; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED; TREMOR;

EID: 0030984046     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870120503     Document Type: Article

References (7)

1. Birkmayer W, Hornykiewicz O. The effect of L-D, 4-hydroxyphenylalanine (= DOPA) on akinesia in Parkinsonism. Wien Klin Wochenschr 1961:73:787-788.
2. Barbeau A. The pathogenesis of Parkinson's disease: a new hypothesis. Can Med Assoc J 1962:87:802-807.
3. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-379.
4. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neural 1987;45:19-34.
5. Rajput AH, Rozdilsky B, Rajput A, Ang L. Levodopa efficacy and pathological basis of Parkinson syndrome. Clin Neuropharmacol 1990;13:553-558.
6. Alvord EC Jr, Forno LS, Kusske JA, Kauffman RJ, Rhodes JS, Goetowski CR. The pathology of parkinsonism: a comparison of degenerations in cerebral cortex and brainstem. Adv Neural 1974; 5:175-193.
7. Jellinger K. The pathology of parkinsonism. In: Marsden CD, Fahn S, eds. Movement disorders 2. London: Butterworths, 1987:124-165.